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SCIENCE ADVANCES | RESEARCH ARTICLE
CELL BIOLOGY

A novel landscape of nuclear human CDK2 substrates
revealed by in situ phosphorylation
Yong Chi1,2, John H. Carter3, Jherek Swanger1, Alexander V. Mazin4, Robert L. Moritz2, Bruce E. Clurman1*
Cyclin-dependent kinase 2 (CDK2) controls cell division and is central to oncogenic signaling. We used an “in
situ” approach to identify CDK2 substrates within nuclei isolated from cells expressing CDK2 engineered to use
adenosine 5′-triphosphate analogs. We identified 117 candidate substrates, ~40% of which are known CDK substrates. Previously unknown candidates were validated to be CDK2 substrates, including LSD1, DOT1L, and Rad54.
The identification of many chromatin-associated proteins may have been facilitated by labeling conditions that
preserved nuclear architecture and physiologic CDK2 regulation by endogenous cyclins. Candidate substrates
include proteins that regulate histone modifications, chromatin, transcription, and RNA/DNA metabolism. Many
of these proteins also coexist in multi-protein complexes, including epigenetic regulators, that may provide new
links between cell division and other cellular processes mediated by CDK2. In situ phosphorylation thus revealed
candidate substrates with a high validation rate and should be readily applicable to other nuclear kinases.

INTRODUCTION

Advanced mass spectrometry (MS) and quantitative phospho
proteomics enable the identification of large sets of protein phospho
rylation sites to comprehensively identify protein kinase substrates
(1–4). However, despite many advances, determining which phos
phorylation sites are direct and physiologic targets of a specific kinase
remains challenging. Analog-sensitive kinases (AS-kinases) are an im
portant tool for discovering kinase substrates. AS-kinases contain a
mutation in a conserved “gatekeeper” residue that normally functions
to restrict active site access to adenosine 5′-triphosphate (ATP; but
not other nucleotides) (3, 5–7). Replacing the gatekeeper residue with
a smaller amino acid renders AS-kinases capable of using bulky ATP
analogs that cannot be used by normal kinases. By using bulky ATP
analogs in combination with AS-kinases in various ways, the activity
of an AS-kinase can be isolated from that of other cellular kinases.
In vitro applications of AS-kinases use ATP analogs to directly
tag substrates with a label that distinguishes them from other cellular
phosphoproteins [reviewed in (3, 6)]. However, because ATP analogs
cannot enter intact cells, these approaches require in vitro conditions
that can be prone to artifacts. For example, the use of highly active
recombinant AS-kinases and cell lysates (in which cellular contexts
are lost) can produce false-positive identifications that may greatly
increase the experimental work needed to validate candidate sub
strates. In contrast, in vivo applications of AS-kinases typically
identify proteins that are differentially phosphorylated in cells treated
with highly specific AS-kinase inhibitors, sometimes in the context
of AS mutations engineered into endogenous kinases (3, 6). While
these methods are not prone to in vitro artifacts, they cannot readily
distinguish direct substrates from phosphorylations that may be
indirectly regulated by AS-kinase inhibition because substrates are
not directly labeled by the AS-kinase.
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Cyclin-dependent kinases (CDKs) are holoenzymes consisting
of catalytic (CDK) and regulatory (cyclin) subunits that regulate
cellular process by phosphorylating complex substrate networks
(8, 9). Many mammalian CDKs—including CDK1, CDK2, CDK5,
CDK7, and CDK9—have proven amenable to AS mutations and have
been studied using both direct and indirect approaches (10–18).
Cdk2 is activated by cyclin E and cyclin A. Cyclin E-Cdk2 regulates
cell cycle re-entry, G1 progression, and S phase entry, whereas
cyclin A–Cdk2 acts later in the cell cycle, where it coordinates S phase
progression and functions in G2 and M phase cells. In previous
work, we developed an in vitro approach using recombinant cyclin
A/AS-CDK2 and thiophosphate labeling to identify >100 candidate
cyclin A–CDK2 substrates in human cell lysates (19). The use of a
thiophospho-ATP analog allowed a biochemical enrichment–based
strategy and prevented ATP analog hydrolysis in cell lysates. Shokat
and colleagues (10) also developed a thiophosphate-based method
to study AS-CDK1 in vitro, which used alternate thiophosphate
chemistry. These studies revealed candidate substrates common to
both CDK2 and CDK1 and unique candidates for each kinase.
However, the extent to which any of these proteins is predominantly
a CDK1 versus CDK2 substrate in vivo is not known.
Because of its crucial roles in normal and neoplastic signaling,
we sought to identify high confidence CDK2 substrates using con
ditions that maintain near-physiologic CDK2 activity and preserve
nuclear context and architecture. In this approach, termed “in situ
phosphorylation,” we first stably expressed ectopic AS-CDK2 in
cells, which is activated by endogenous cyclins and thus subject to
near-normal regulation. We then isolated nuclei from cells express
ing either wild-type CDK2 (WT-CDK2) or analog-sensitive CDK2
(AS-CDK2) and performed in situ substrate thiophosphorylation
by incubating the nuclei with an ATP--S analog. These conditions
allow substrates to be phosphorylated in conditions that better pre
serve CDK2’s normal subcellular interactions with its substrates.
We subsequently used biochemical enrichment and MS to identify
candidate substrates.
We identified ~150 AS-CDK2–specific thiophosphopeptides and
117 candidate CDK2 substrates. Remarkably, ~43% of these proteins
are known CDK substrates, indicating that a high proportion of the
candidates are physiologic CDK2 substrates. Moreover, we found
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that each of the candidates we tested was directly phosphorylated by
CDK2 in vitro or in vivo, further supporting the idea that candidates
identified through in situ phosphorylation contain a high proportion of
bona fide CDK2 substrates. Many previously unidentified candidates
are chromatin-associated proteins with roles in histone modification
and chromatin remodeling; DNA metabolism, damage, and repair;
and transcription and RNA metabolism, and whose identification was
likely allowed by maintaining the nuclear contexts within which
CDK2 normally functions. In summary, in situ conditions led to the
efficient and more confident identification of CDK2 substrates.
These methods should be readily applicable to other nuclear kinases
with complex substrate networks.
RESULTS

Developing AS-CDK2 cells and substrate
thiophosphorylation in isolated cell nuclei
We used retroviral transduction to generate pools of human embryonic
kidney–293 (HEK293) cells that stably express either WT-HACDK2
or AS-HACDK2 [hemagglutinin (HA) tagged] at levels slightly less
than endogenous CDK2 (Fig. 1A). A previous study revealed that
AS-CDK2 has impaired cyclin A binding that prevents AS-CDK2
from effectively competing with endogenous CDK1 and CDK2 for
cyclin A binding (12). Accordingly, AS-CDK2 had less kinase activity
than WT-CDK2, as assayed by immunoprecipitation kinase assays
using antibodies against the HA-tag (specific to ectopic CDK2), total
CDK2, or cyclin E (Fig. 1, B and C). To overcome this defect, we
inhibited endogenous CDK2 by using lentiviruses encoding a short
hairpin RNA (shRNA) targeting the CDK2 3′ untranslated region
(3′UTR; which is not present in the retroviral CDK2 complementary
DNAs), which silenced endogenous CDK2 to almost undetectable
levels (Fig. 1A). As predicted, endogenous CDK2 knockdown increased
AS-CDK2 activity, presumably by enhancing cyclin association
(Fig. 1, B and C). However, AS-HACDK2 activity remained lower
than WT-HACDK2 activity even after endogenous CDK2 knockdown
(Fig. 1B). Silencing endogenous CDK2 thus yielded detectable
AS-CDK2 activity that was somewhat less than endogenous CDK2
activity, rather than supraphysiologic activity.
Since the cell membrane is impermeable to nucleotides, we isolated
nuclei using hypotonic methods to help preserve nuclear integrity
and determined that ATP--S enters isolated nuclei and that proteins
could be readily labeled by incubating nuclei with ATP--S (table S1).
We then used nuclei isolated from WT- and AS-HACDK2 cells in
conjunction with N6-(2-phenylethyl)–ATP--S (PE–ATP--S) to
directly label nuclear CDK2 substrates (Fig. 2A). Cells have high
concentrations of ATP (>1 mM) that competes with PE–ATP--S
for kinase occupancy. We thus included Mn2+ in the in situ kinase
reaction, which improves thiophosphate labeling by allowing more
effective competition with cellular ATP (20). Last, CDK2 substrates
that are already highly phosphorylated by CDK2 in vivo may not
be additionally labeled by the thiophospho-ATP analog in situ. We
thus briefly pretreated cells with a CDK inhibitor (roscovitine) before
harvesting and isolating nuclei to inhibit endogenous CDK2 and allow
substrate dephosphorylation before labeling in situ (Fig. 2A).
Thiophosphopeptide recovery and identification of high
confidence nuclear CDK2 substrates
Nuclei were lysed after thiophosphorylation and digested with trypsin,
and the resultant tryptic peptides containing either thiophosphate
Chi et al., Sci. Adv. 2020; 6 : eaaz9899
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Fig. 1. Characterization of AS-CDK2 activity. (A) HEK293 cells [control (con)] and
HEK293 cells stably expressing WT-HACDK2 and AS-HACDK2 were transduced with
lentiviral vectors expressing control or one of two different CDK2 shRNAs (#1
and #2) for 2 days. Cell lysates were immunoblotted with anti-CDK2 and anti–-tubulin
(loading control) antibodies. The positions of CDK2 and ectopic HA-CDK2 are indicated. (B and C) Lysates from the above cells were immunoprecipitated (IP) with
anti-HA (B), anti-CDK2, and anti–cyclin E antibodies (C), and histone H1 kinase
assays were carried out in the presence of -32P-ATP.

or cysteine were bound to a disulfide resin (Thiopropyl Sepharose
6B) as previously described (Fig. 2, B and C) (19)). We developed a
new method to elute thiophosphopeptides from the disulfide beads
with dithiothreitol (DTT), which retains the thiophosphate tag
within the eluted peptides (thereby providing a unique mass signature
for AS-CDK2 substrates) and allows the elution of cysteine-containing
thiophosphopeptides. Although DTT elutes a large excess of peptides
that simply contain cysteine, current MS instruments easily handle
the additional sample complexity, and these peptides were readily
excluded from subsequent analyses. Moreover, the mildly acidic
conditions used favor the binding and elution of thiophospho
peptides over cysteine-containing peptides (21).
We performed a large-scale experiment, in which four replicates
of cell nuclei from WT- or AS-HACDK2 cells were labeled with
PE–ATP--S (see Materials and Methods). We identified 4592
unique peptides, of which 464 were unique thiophosphopeptides
(about 10% of the total eluted peptides), and almost all (~99%) of
the remaining peptides contained cysteine (table S2). Among the
326 unique “stripped” thiophosphopeptides (distinguished only on
the basis of primary sequence), 166 thiophosphopeptides were
found only in AS-CDK2 samples, 32 only in control WT-CDK2
samples, and 128 in both (table S3). Candidate CDK2 substrates
were defined as containing thiophosphopeptides that (i) were present
only in AS-CDK2 samples and (ii) have primary sequences that
contain proline-directed CDK phosphorylation motifs (serine or
threonine followed by a proline, termed “S/T-P”). Applying these
criteria, 156 of 166 (93%) of the CDK2-AS–specific thiophospho
peptides had at least one S/T-P site, which corresponds to 117
2 of 10
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Fig. 2. Schema for identification of CDK2 substrates using an in situ nuclear labeling assay. (A) Scheme for in situ labeling. Asynchronously growing HEK293 cells
stably expressing WT-CDK2 (AS-CDK2) were pretreated with roscovitine and harvested by trypsinization. Nuclei were isolated as depicted, incubated with PE–ATP--S to
allow thiophosphate labeling of proteins, and subsequently lysed (see Materials and Methods). (B) Scheme for thiophosphopeptide isolation and identification. Labeled
nuclear extracts were digested with trypsin. The resulting peptides were incubated with disulfide beads, which capture both thiophosphopeptides and cysteine-containing
peptides. Beads were eluted with dithiothreitol (DTT), and the eluted peptides were subjected to liquid chromatography coupled to tandem MS to identify the thiophosphopeptides. Specific thiophosphopeptide identifications that carried proline-directed phosphorylation motifs and were present in the AS-CDK2 cells but not control
WT-CDK2 cells were considered as candidate CDK2 substrates. (C) Schematic of thiophosphopeptide and cysteine-containing peptide elution from disulfide beads by DTT.

unique proteins. The Comet search engine localized the presumptive
thiophosphorylation site to be the proline-directed S/T-P residues
in 148 of 156 (95%) of the AS-specific S/T-P thiophosphopeptides
(tables S3 and S4). Most (94%) of these 117 substrates are nuclear
proteins, and only 33 of 117 had been found in our previous in vitro
studies. About 95% of the phosphorylation sites carried the full
CDK consensus motif S/T-P-X-R/K (where X is any amino acid),
and ~95% of these phosphorylations have been reported in largescale in vivo phosphoproteome analyses (22–25). We recovered six
cysteine-containing thiophosphopeptides representing four unique
proteins (tables S3 and S4). Fifty of 117 (43%) candidate substrates
are known CDK substrates, indicating a remarkably high proportion
of physiologic CDK substrates within the candidate list generated in
situ (table S4).
In addition to known CDK substrates, we found a novel land
scape of candidate CDK2 substrates, most of which function within
key nuclear processes, including cell cycle control, histone modifica
tion and chromatin organization, DNA replication and repair, tran
scription, and RNA metabolism (Fig. 3A). The high proportion of
candidates associated with chromatin modification, DNA metabolism,
and transcription is likely the result of in situ conditions that pre
serve cyclin-CDK2 chromatin associations. For example, we identi
fied 11 proteins that regulate histone modifications as candidate
substrates, eight of which are previously unknown (DOT1L, JARID2,
Chi et al., Sci. Adv. 2020; 6 : eaaz9899
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KAT6A, LSD1, MSL1, MSL3, SETDB1, and NSD2) and three of which
are known CDK substrates (KMT2B, PHF8, and SUV39H1). We also
found candidates with broader roles in chromatin remodeling (e.g.,
BCOR, BCL11A, DMAP1, INO80E, and SMARCA5) and known
CDK substrates with chromatin remodeling functions (e.g., BRD4).
Similarly, we identified many proteins that regulate transcription
and RNA metabolism, and these include many previously unknown
candidate CDK2 substrates (see Discussion).
We further interrogated the relationships between the substrates
in this network by searching protein-protein interaction databases.
First, we manually curated the known physical interactions between
all of the substrates with one another by using BioGRID 3.5 (https://
thebiogrid.org) (table S5) (26). We found extensive physical inter
actions between many of the CDK2 substrates, reinforcing the master
regulatory roles that CDK2 plays in processes such as cell division
and DNA repair and replication. Next, we examined whether and
how candidate substrates coexist within known multiprotein complexes
by using the Corum database (https://mips.helmholtz-muenchen.de/
corum/) (27). Many known and candidate substrates coexist within
these defined Corum complexes in both expected and unexpected
ways, suggesting that CDK2 may globally regulate these complexes
through phosphorylating multiple subunits thereof (Fig. 3, B and C,
and see Discussion). One particularly notable finding was the
co-occurrence of candidate CDK2 substrates in complexes with crucial
3 of 10
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Fig. 3. Functional categorization of CDK2 candidate substrates. (A) Candidate substrates are grouped based on select gene ontology processes and with manual
curation. Boldfaced proteins denote known CDK substrates. (B to G) Examples of CDK2 substrates and candidate substrates (green subunits) co-occurring in known
Corum complexes. The Corum complex identification number is shown in the middle of each depicted complex. The following complexes are shown: (B) BASC complex,
6 of 12 components depicted; (C) Emerin complex 24, 6 of 6 components depicted; (D) NuRD complex, 6 of 7 components depicted; (E) LSD1 complex, 6 of 14 components
depicted; (F) XFIM complex, 5 of 5 components depicted; and (G) SNF2h-cohesin-NuRD complex, 6 of 16 components depicted.

epigenetic functions, particularly those that contain both LSD1 and
the histone deacetylase 1/2 (HDAC1/2) (Fig. 3, D to G, and see
Discussion). References for each of these specific complexes can be
found on the Corum website.
In vitro validation of select candidate CDK2 substrates
The high proportion of known CDK substrates found in our screen
suggested that many candidates may also be bona fide CDK2 sub
strates. We thus determined whether a group of nine candidates
(representing proteins that were readily immunoprecipitated from
transfected cells) were phosphorylated by recombinant cyclin A–CDK2
in vitro. These include (i) NSD2, a SET-domain histone lysine
methyltransferase; (ii) DMAP1, a component of the NuA4 histone
acetyltransferase complex; (iii) LSD1/KDM1A, a histone H3 Lys-4
demethylase; (iv) DOT1L, a methyltransferase that acts on Lys79 of
histone H3; (v) BCL11A, a transcription factor (TF) associated with
chromatin remodeling; (vi) PRPF3, a component of the precatalytic
spliceosome; (vii) MSL3, a chromatin remodeling protein and
regulator of histone H3 acetylation; and (viii) GTF3C2, a general TF
required for RNA polymerase III–mediated transcription. Last, we
recently validated Rad54 phosphorylation on both T31 and S59 by
CDK2 in vitro and found that S49 phosphorylation inhibits Rad54’s
branch migration activity (28).
We immunoprecipitated each of these nine proteins from trans
fected HEK293 cells and tested their ability to be phosphorylated by
recombinant cyclin A–CDK2 in vitro using 32P-ATP (Fig. 4). All
Chi et al., Sci. Adv. 2020; 6 : eaaz9899
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nine of these in situ candidates were validated to be direct CDK2
substrates in vitro. In the case of DMAP1, it was necessary to elute the
immunoprecipitated protein for it to be phosphorylated (Fig. 4, C and F),
whereas the other substrates were readily phosphorylated while bound
to beads (Fig. 4, A and B). Immunoblots of the immunoprecipitated
substrates are shown in Fig. 4 (D to F).
In vivo validation of select candidate CDK2 substrates
We next determined whether any of three of these previously un
known substrates (RAD54, DOT1L, and LSD1) are phosphorylated
by CDK2 in vivo by either generating phosphosite-specific antibodies or
using commercial phospho-specific antibodies. Because we identified a
RAD54 phosphopeptide containing T31 in our substrate screen, we
generated an anti-Rad54 antibody that detects phosphorylated T31 in
a phosphatase-sensitive manner (fig. S1A). The anti-pT31 antibody
also exhibited a small amount of reactivity against unphosphorylated
Rad54, which was eliminated when the epitope was deleted (fig. S1B).
Endogenous RAD54 was hypophosphorylated on T31 in asyn
chronous cells, but T31 phosphorylation rapidly increased when cells
were treated with the phosphatase inhibitor okadaic acid, suggesting
that endogenous Rad54 T31 phosphorylation is highly labile and
opposed by a phosphatase (fig. S1C). Phospho-T31 was also readily
detectable on ectopic Rad54 in vivo (without okadaic acid treat
ment); this was reduced by brief CDK inhibition with roscovitine
(Fig. 5A) and, conversely, increased by cyclin A–CDK2 overexpression
(Fig. 5B). Residual Rad54 T31 phosphorylation in roscovitine-treated
4 of 10
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Fig. 4. Validation of select CDK2 candidate substrates in vitro. (A) FLAG-tagged PRPF3, Myc-tagged BCL11A, and HA-tagged MSL3 and GTF3C2 were expressed in HEK293
cells and immunoprecipitated from cell lysate using antibodies against the tag. Washed immunoprecipitates were phosphorylated using purified cyclin A–CDK2 (or no
kinase control) in the presence of 32P-ATP and detected by autoradiography. Histone H1 kinase assay was used as control. oe, overexposure. Lane 9 was empty. Asterisk (*)
marks the expected band of the substrates. (B) FLAG-tagged NSD2, LSD1, and DOT1L were analyzed as in (A). (C) FLAG-tagged DMAP1 was analyzed as in (A), except that the
washed immunoprecipitates were first eluted with a FLAG peptide and fractions of the eluate were used in the kinase assay. Lane 2 was empty. (D and E) Immunoblots (IB)
of a fraction of the corresponding immunoprecipitates shown in (A) and (B) using the antibodies against the tag. In (D), lanes 2 and 4 were empty. (F) Immunoblot of the gel
in (C) after autoradiography using FLAG antibody.

cells likely reflects either incomplete T31 dephosphorylation during
the brief period of CDK2 inhibition or a roscovitine-insensitive
kinase that also phosphorylates T31. Because CDK2 directly phos
phorylates T31, these data are consistent with the idea that CDK2
directly phosphorylates RAD54 on T31 in vivo, although it is formally
possible that another T31 kinase is up-regulated by cyclin A–CDK2
overexpression. Last, because CDK activity is highest in mitosis, we
studied endogenous Rad54 in cells arrested in prometaphase with
nocodazole (see flow profiles in fig. S1D) and found high levels
of T31 phosphorylation that was almost completely inhibited by
two CDK inhibitors, roscovitine and RO-3306 (a CDK1 inhibitor)
(Fig. 5C). Thus, endogenous RAD54 is phosphorylated in mitosis
on T31, likely by CDK2, CDK1, or both. Because we used a pT31-
specific antibody, we were unable to assess Rad54 S49 phosphoryl
ation in vivo.
To study DOT1L, we made a phospho-specific antibody against
its pS297 epitope. We chose S297 instead of the S775 site identified
in our screen because S297 is a CDK consensus site that falls within
a conserved catalytic domain of DOT1L. We found that the anti
body was specific for S297 (fig. S1F) and that coexpression of
DOT1L with cyclin A–CDK2 strongly stimulated DOT1L S297
phosphorylation (Fig. 5D). We were unable to detect endogenous
DOT1L protein and thus could not study its phosphorylation.
Chi et al., Sci. Adv. 2020; 6 : eaaz9899
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Last, we performed similar validation experiments for LSD1.
Although we failed to make a phospho-specific antibody against T59
(the site we identified by MS), a commercial phospho-T/P antibody
specifically detected T59 phosphorylation of LSD1 in vitro, as
shown by the strong LSD1 phosphorylation after cyclin A–CDK2
treatment and the lack of detectable phosphorylation of an LSD1
T59A mutant (fig. S1E). Using this phospho-T/P antibody, we found
that endogenous LSD1 is phosphorylated in vivo and strongly stimu
lated by cyclin A–CDK2, suggesting that cyclin A–CDK2 phosphorylates
LSD1 on T59 in vivo (Fig. 5E). Endogenous LSD1 was also strongly
phosphorylated in nocodazole-treated cells in a roscovitine-dependent
and RO-3306–dependent manner (Fig. 5F). This phosphorylation
was completely eliminated when an ectopic T59A LSD1 mutant was
compared with ectopic WT LSD1, indicating that pT59 is also
recognized by the pT/P antibody in vivo (Fig. 5G). We also studied
synchronized cells to determine whether LSD1 T59 phosphoryl
ation exhibited cell cycle regulation. By following cells arrested in
early S phase by a double thymidine block and release, we found
that T59 phosphorylation was lowest in G1 phase, begins to rise in
S phase, and peaks in G2-M phase (Fig. 5, H and I). This pattern is
highly reflective of CDK2 activity during the cell cycle, although we
were unable to directly test this because CDK2 inhibition prevents
cell cycle progression after cell synchronization and release. In
5 of 10
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Fig. 5. CDK2-dependent phosphorylation of RAD54, DOT1L, and LSD1 in vivo and cell cycle regulation of LSD1 T59 phosphorylation. (A) Myc-tagged RAD54 WT
and T31A mutant were immunoprecipitated from transfected HEK293 cells and immunoblotted for T31 phosphorylation and total RAD54 protein. Roscovitine (Rosc) was
added 2 hours before harvest. Untransfected cells, control. Arrow denotes endogenous RAD54. (B) HEK293 cells were cotransfected with myc-tagged RAD54 and myctagged cyclin A–HACDK2 or vector control. RAD54 was immunoprecipitated and immunoblotted for T31 phosphorylation and total RAD54 protein (top), and the cell
lysates were immunoblotted for cyclin A and CDK2 expression (bottom). -Tubulin–loading control. (C) HEK293 cells were treated with nocodazole (Noc) for 17 hours, and
endogenous RAD54 was immunoprecipitated and immunoblotted for T31 phosphorylation and for total RAD54 protein. Roscovitine or RO-3306 was added 1 hour before
harvest. “Noc-” indicates asynchronous cells. (D) FLAG-tagged DOT1L was analyzed as in (B). DOT1L phosphorylation was detected using an anti–phospho-S297 DOT1L
antibody. Untransfected cells, control. (E) HEK293 cells were transfected with myc–cyclin A and HA-CDK2 or vector control. Endogenous LSD1 was immunoprecipitated
and immunoblotted for T59 phosphorylation using anti–phospho-TP antibody and also for total LSD1 (top). Cell lysates were immunoblotted for cyclin A and CDK2
expression (bottom). -Tubulin, loading control. (F) Endogenous LSD1 was analyzed as in (C). (G) FLAG-tagged LSD1 WT and T59A mutant were immunoprecipitated from
transfected HEK293 cells that were treated with nocodazole for 17 hours and immunoblotted for T59 phosphorylation and total LSD1. (H) HEK293 cells were synchronized
at the G1-S boundary by double thymidine block and released. Cells were harvested at indicated times. Endogenous LSD1 was immunoprecipitated and immunoblotted
for T59 phosphorylation using anti–phospho-TP antibody and also for total LSD1 (top). Cell lysates were immunoblotted for LSD1 and -tubulin (bottom). (I) Cell cycle
profiles at the indicated times using flow cytometry.

summary, these data support that Rad54, DOT1L, and LSD1 are
in vivo substrates of CDK2.
DISCUSSION

CDK2 has critical roles in cell division, DNA replication, DNA
damage and repair, and cell cycle checkpoints. Moreover, CDK2
mediates many oncogenic pathways and responses to anti-neoplastic
agents. While many CDK2 substrates in these pathways have been
identified, crucial aspects of normal and neoplastic CDK2 function
remain unknown. We thus developed in situ phosphorylation to enable
future mechanistic studies by identifying previously unknown physio
Chi et al., Sci. Adv. 2020; 6 : eaaz9899
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logic substrates. In addition to many known CDK substrates, we identi
fied ~70 previously undiscovered candidate substrates. Validation studies
of a set of nine candidates confirmed that each was a CDK2 substrate,
suggesting that many (or most) candidates will be found to be bona
fide substrates. In situ phosphorylation identified a very different
set of CDK2 substrates from those found in vitro, including many
chromatin-associated proteins that we speculate were discovered
because in situ kinase reactions are performed under conditions in
which the normal subcellular relationships between CDK2 and its
nuclear substrates are preserved.
One particularly interesting set of candidates includes enzymes that
modify histones and chromatin. CDK2 affects histone abundance
6 of 10
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and activity in several ways: (i) by direct histone phosphorylation
(29), (ii) by regulating histone transcription through NPAT phos
phorylation (30), and (iii) through phosphorylation of histone-
modifying enzymes, such as EZH2, which controls epigenetic gene
silencing (31). Here, we identify several candidate CDK2 substrates
with important roles in histone modification (DOT1L, JARID2,
KAT6A, LSD1, MSL1, MSL3, SETDB1, and NSD2) or broader roles
in chromatin remodeling (e.g., BCOR, DMAP1, INO80E, and
SMARCA5).
Another interesting group of candidate substrates is composed
of transcriptional regulators and TFs, which include proteins with
roles in cancer (e.g., BCL11A and AF9) and more general transcrip
tional functions (e.g., GTF2I). We also found several proteins
with roles in splicing and RNA metabolism (e.g., PRP3, PRP16/
DHX38, and SRRM2). Again, we speculate that CDK2-mediated
phosphorylation of these transcriptional and mRNA regulators
may thus provide important mechanisms linking control of cell
division with gene expression. Last, while CDK2’s roles in DNA
replication, damage, and repair are well known, we identified previ
ously undiscovered putative substrates with important roles within
these well-studied pathways, including RIF1, RAD54, and XRCC1.
Future studies are needed not only to validate these candidates
but also to understand how they are regulated by CDK2-mediated
phosphorylation during the cell cycle.
As noted above, many of the CDK2 substrates we found coexist
within known complexes, suggesting that CDK2 may regulate these
complexes by targeting multiple components for phosphorylation,
perhaps within the context of the complexes themselves. For example,
while many cell cycle and DNA repair proteins are found in com
plexes with canonical functions (e.g., BASC complex; Fig. 3B), these
proteins are also found in complexes with unknown functions, such
as the Emerin 24 complex (Fig. 3C). Studies of these atypical com
plexes may reveal new functions for CDK2.
One particularly interesting finding involves the presence of
multiple CDK2 substrates within complexes with epigenetic func
tions, many of which contain both the LSD1 histone demethylase
and the HDAC1/2 histone deacetylases. These complexes regulate
gene expression through coordinated chromatin modification, in
cluding histone demethylation and acetylation. In addition to LSD1
and HDACs, these complexes also contain unique subunits, which
include previously undiscovered CDK2 substrates, including RREB1,
MTA1, SMARCA5, ZMYM3, and GTF2I (Fig. 3, D to G). The pres
ence of multiple CDK2 substrates within these epigenetic regulators
suggests that CDK2 may directly affect their function via direct
phosphorylation of these components, perhaps in cell cycle–specific
ways. There are numerous additional examples of multiple CDK
substrates contained within complexes that regulate transcription,
cell division, ribosomal biogenesis, and other cellular processes. We
speculate that these substrates link the control of cell division with
the regulation of gene expression at many levels via their phosphoryl
ation by CDK2.
Validation work is a bottleneck for all proteomic screens, and it
is highly desirable to improve the ability of these screens to identify
physiologic substrates. While we initially attempted to label CDK2
substrates in living cells using different delivery systems, we were
unable to deliver ATP--S analogs into live cells in an efficient and
noninvasive way. We thus sought to preserve nuclear contexts while
also allowing direct substrate labeling by performing in situ kinase
assays in isolated nuclei. This in situ approach has notable advantages,
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including (i) maintenance of nuclear structures and the cellular
contexts within which CDKs normally function, (ii) near-physiologic
CDK2-AS abundance and activity, and (iii) maintaining thio
phosphate signatures after elution, which allows more confident
identification of peptides phosphorylated by the AS-kinase. As a
result, the list of candidate CDK2 substrates was highly enriched for
known CDK substrates, and all of the candidates that we studied
were validated to be phosphorylated by CDK2. We thus believe that
it is likely that many (or most) of the candidates that remain untested
will prove to be bona fide CDK2 substrates.
Although we confirmed a high rate of validation, several factors
may still contribute to false-positive substrate identifications. For
example, nearly half of the thiophosphopeptides we identified were
found in both CDK-AS and CDK2-WT kinase assays, indicating
that some AS-CDK2–independent background labeling occurs, with
a signal-to-noise ratio of about 1 (table S3). This background likely
results from cellular kinases known to use bulky ATP analogs (32).
While it is also possible that PE–ATP--S was hydrolyzed during
the kinase reaction (thereby generating ATP--S that can be used by
many cellular kinases), we previously found that ATP--S and PE–
ATP--S are stable in whole-cell lysates, and this is likely also true in
isolated nuclei (19). Despite this background, by requiring that
thiophosphopeptides contain S/T-P motifs to be considered as sub
strates, the vast majority of background thiophosphopeptides were
eliminated from subsequent analyses. The few thiophosphopeptides
present in the “WT-CDK2–only” samples indicates that our MS
analyses did not reach saturation with respect to peptide identifica
tions. Thus, some “AS-specific” candidate substrates may drop out
if they are found in WT-CDK samples with additional replicates.
However, thus far, our validations have not revealed many false-
positive identifications. Last, because our methods require isolating
intact nuclei, we could only identify CDK2 substrates in inter
phase cells. This limitation may explain why we did not detect elon
gation factor 2, which is a cytoplasmic protein phosphorylated by
CDK2 only in mitosis (33).
In conclusion, we describe an in situ implementation of AS-CDK2
for substrate discovery that allows CDK2 to phosphorylate its sub
strates under near-physiologic conditions. We also developed method
ological advances to identify candidate AS-CDK2 substrates more
definitively and comprehensively. As a result, we found a high per
centage of known CDK substrates and a high rate of validation for
previously undiscovered candidates. Moreover, the enrichment for
chromatin-associated proteins with important roles in processes such
as gene expression and DNA and RNA metabolism suggests that
in situ conditions may allow new types of substrates to be identified
for CDKs and other nuclear kinases that function within specific
nuclear contexts. These methods should be readily adaptable to study
other nuclear kinases that are amenable to AS mutations.
MATERIALS AND METHODS

Experimental design
The objectives of this study were to develop a near physiologic envi
ronment for substrate phosphorylation by AS-CDK2. The primary
study design provided two mechanisms to accomplish this goal.
The first was to stably express AS-CDK2 at normal abundance and
to allow the exogenous AS-CDK2 to be activated by endogenous
cyclins, which are rate limiting for CDK2 activation. The second
was to isolate nuclei and allow substrates to be phosphorylated
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by AS-CDK2 in a nearly normal nuclear environment. We used
substrate thiophosphorylation for several reasons: (i) We previously
have characterized the ability of AS-CDK2 to use and hydrolyse
ATP--S, (ii) we previously developed efficient biochemical methods
to enrich and identify thiophosphopeptides by MS, and (iii) thio
phosphate allows AS-CDK2 substrates to be easily distinguished from
other cellular phosphopeptides. As shown in Fig. 2, the overall
design consisted of the following steps: (i) stable expression of ASCDK2 in HEK293A cells, (ii) inhibition of endogenous CDK2 by
shRNA, (iii) treatment of cells with roscovitine to inhibit endoge
nous CDKs, (iv) isolation of nuclei and incubation with PE–ATP--S,
(v) thiophosphopeptide enrichment and identification by MS, and
(vi) substrate validation in vitro and in vivo.
Cell culture, transfection, retroviral transduction,
and drug treatments
The HEK293 was obtained from the American Type Culture Col
lection, tested for mycoplasma and genetically authenticated during
the course of this study. HEK293 cells were cultured in Dulbecco’s
modified Eagle’s medium (11965-092, Gibco), which was supplemented
with 10% (v/v) fetal bovine serum (10437-028, Gibco), penicillin
(100 U/ml), and streptomycin (100 g/ml; 15140-122, Gibco).
Transient transfections were carried out using calcium phosphate.
HEK293 cells stably expressing C-terminally HA-tagged WT-CDK2
or CDK2-F80A (AS-CDK2) were generated via retroviral transduc
tion using a pBabe-based vector (puromycin) as previously described
(34). For CDK2 knockdown via small hairpin RNA, cells were
transduced with lentiviruses encoding nontargeting control shRNA
or two different shRNAs directed to noncoding regions of CDK2
mRNA (see below). Cells were harvested 2 days after infection without
selection, and shRNA expression was confirmed by green fluorescent
protein coexpression. Nocodazole (M1404, Sigma-Aldrich) was used
at 40 ng/ml, for 17 hours, roscovitine (R7772, Sigma-Aldrich) was used
at 25 M for 1 to 2 hours where indicated, and RO-3306 (sc-358700;
Santa Cruz Biotechnology) was used at 1 M for 1 hour. Okadaic acid
(O-2220, LC Laboratories) was used at 200 nM for 90 min.
Antibodies, plasmids, enzymes, and other reagents
The following antibodies were used: Myc tag (1:5; 9E10 hybridoma
supernatant, prepared in house), HA-tag (12CA5 hybridoma super
natant; prepared in-house), FLAG M2 (1:4000; F1804, Sigma-Aldrich),
CDK2 (1:1000; D-12, sc-6248, Santa Cruz Biotechnology), cyclin A
(1:1000; gift from J. Roberts, Fred Hutchinson Cancer Research
Center), cyclin E (1:1000; HE111, sc-248, Santa Cruz Biotechnology),
-tubulin (1:1000; sc-17787; Santa Cruz Biotechnology), RAD54
(1:1000; F-11, sc-374598, Santa Cruz Biotechnology), LSD1 (1:5000;
A300-215A, Bethyl Laboratories), DOT1L (1:2000; A300-953A, Bethyl
Laboratories), and phospho-T/P (1:1000; 9391S; Cell Signaling
Technology). Phospho-T31 RAD54 and phospho-S297 DOT1L
antibodies were custom made by Yenzym Antibodies (San Francisco),
raised against the synthetic phosphopeptides CEDWQPGLV-pTPRKRK (RAD54) and CMRVVEL-pS-PLKGSVS (DOT1L).
Substrate expression plasmids were obtained as follows: FLAGDMAP1 (C. Kim, Hanyang University), FLAG-NSD2 (J. Licht,
University of Florida), HA-MSL3 (J. Cotes, Laval University),
HA-GTF3C2 (R. White, University of York), FLAG-PRPF3 (S. M.
Iguchi-Ariga, Hokkaido University), and N-terminal FLAG-DOT1L
and C-terminal HA-DOT1L (Y. Zhang, Harvard). RAD54 was cloned
into the pCS2+ vector with a C-terminal 5× myc tag. The deleted
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sequence for myc-RAD54-T31A8 was EDWQPGLV. N-terminal
3× FLAG-tagged LSD1 was cloned into a pCS2+ vector. BCL11A
was cloned into the pCS2+ 5myc vector. Cyclin A and CDK2 expres
sion plasmids were pCS2+ 6 myc–cyclinA (gift from J. Roberts, Fred
Hutchinson Cancer Research Center) and pCMV-CDK2HA (gift
from S. van den Heuvel, Utrecht University, The Netherlands), re
spectively. All mutants were generated by site-directed mutagenesis
using the QuikChange method (Stratagene) and sequenced. Lenti
viral plasmids using the pGIPZ vector were purchased onsite,
and the CDK2 3′UTR targeting sequences of the two shRNAs used
were AGGATGAACAATTATATTT (#1) and AGGTTATATC
CAATAGTAG (#2). Lambda protein phosphatase (P0753S) and
recombinant cyclin A–CDK2 were purchased from New England
Biolabs. Recombinant glutathione S-transferase (GST)–cyclin E–CDK2
(33) and GST-Rb (19) were prepared in house. ATP--S was pur
chased from Millipore Sigma (catalog no. 119120). PE–ATP--S
was purchased from BIOLOG Life Sciences Institute (catalog no.
P026, Bremen, Germany).
Immunoblotting, immunoprecipitation, kinase assays,
cell synchronization, and flow cytometry
Immunoblotting, Immunoprecipitation, kinase assays, and flow
cytometry were performed as described (34). Images of full gels for
each figure are shown in fig. S2. For DMAP1 kinase assay, DMAP1
was first eluted from immunoprecipitates with FLAG peptide
(150 g/ml; F4799, Millipore Sigma) and concentrated using a
MicroCon-30 (MRCF0R030, Millipore Sigma-Aldrich). For cell cycle
analysis of LSD1 phosphorylation, HEK293 cells were first synchro
nized by double thymidine block. Briefly, cells were treated with 2 mM
thymidine (T9250, Millipore Sigma-Aldrich) for 16 hours, washed
once with fresh medium, and released into fresh medium supplemented
with 24 M 2′-deoxycytidine (951-77-9, Acros Organics) for 8.5 hours.
Cells were then washed once with fresh medium and treated again
with 2 mM thymidine for 18 hours before releasing into fresh medium
containing 2′-deoxycytidine. Cells were harvested by trypsinization
at various times up to 25 hours, and a fraction of the cells were fixed
for flow cytometry analysis.
Cell nuclei isolation and in situ kinase assay
HEK293 cells stably expressing WT-CDK2 or AS-CDK2 were grown
on eight 15-cm plates (2 days after infection by CDK2 shRNA lenti
virus) to ~80 to 90% confluence (~2 × 107 cells per plate), treated
with roscovitine for 1 hour, and harvested in four replicates (two plates
per cell pellet) by trypsinization, and washed once with cold
phosphate-buffered saline buffer. Each cell pellet (total of eight) was
washed twice by resuspending the cells in 1 ml of cold hypotonic
lysis buffer 1 [10 mM Hepes (pH 7.4), 10 mM KCl, and 2 mM
MgCl2] followed by centrifugation in a microcentrifuge (2000 rpm,
1 min). Cells were resuspended again in 1 ml of hypotonic lysis
buffer 1 and incubated on ice for 15 min. Swollen cells were lysed by
pipetting up and down five to seven times using a 1-ml syringe with
26-gauge needle (305111, Becton, Dickinson and Company). Cell
lysis and intact cell nuclei were verified by staining a small aliquot
with trypan blue (T10282, Life Technologies). The slurry was slowly
added to the surface of 6 ml of cold hypotonic lysis buffer 1 contain
ing 30% sucrose (w/v) in a 15-ml Falcon tube. After centrifugation
in a tabletop centrifuge at 1000g for 10 min, the buffer above the
nuclei pellet was removed, and the pellet was washed three times by
resuspending it in 1 ml of cold hypotonic lysis buffer 1 followed by
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centrifugation in a microcentrifuge (3000 rpm, 1 min). The nuclei
preparation was checked again by staining with trypan blue and
microscope examination. The final nuclei pellet was resuspended in
1.5× volume of hypotonic lysis buffer 1 containing PE–ATP-S (final concentration of 0.5 mM) and MnCl2 (final concentration
of 0.5 mM final) and incubated at 30°C for 30 min. The nuclei slurry
was occasionally mixed by tapping during the course of the reaction.
After the reaction, the nuclei mix was briefly centrifuged (3000 rpm,
15 s) to remove most of the supernatant, and the pellet was flash-frozen
in liquid nitrogen and stored or processed as described below. ATP-S labeling was done similarly starting with two 15-cm plates of
WT-CDK2 cells and labeled at a final concentration of 0.5 mM.
Purification of thiophosphorylated peptides
The frozen nuclei pellet was resuspended in 0.4 ml of hypotonic
lysis buffer 2 [30 mM Hepes (pH 7.4), 10 mM EDTA, and benzonase
(25 U/ml; 70746, Millipore Sigma)]. After incubation on ice for 30
min, Tween-20 was added to a final concentration of 0.1%, and the
sample was sonicated using 20× 1-s pulses. Nuclei debris was pel
leted by centrifugation at 20,000g for 10 min. The supernatant was
digested with sequencing grade modified trypsin (Promega) at 1:20
ratio (w/w), and thiophosphopeptides from the peptide mixture were
purified by binding to 40 l of disulfide beads Thiopropyl Sepharose 6B
(17042001, GE Healthcare) at pH 4.0 as previously described (19).
Washed beads were eluted with 30 l of 25 mM DTT (pH ~4 without
buffering) in 5% acetonitrile/95% H2O at room temperature for
30 min. The eluate was acidified with tris(2-carboxyethyl)phosphine
and formic acid to a final concentration of 5 mM and 0.1%, respec
tively, and analyzed directly by MS.
MS analysis and database search
Phosphopeptides samples were analyzed by Nanoflow liquid chroma
tography (NanoLC) and electrospray ionization tandem MS (MS/MS)
using an LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific)
interfaced with an Agilent 1100 Nano Pump with electronically
controlled split flow. For ATP--S labeling, one sample was analyzed
in duplicate MS runs, and for PE-ATP--S labeling, eight samples
(four WT-CDK2 and four AS-CDK2) were analyzed in duplicate
MS runs (16 MS runs in total). Peptides were loaded in sequence
onto a 75 m (inner diameter) by 15 cm C18 microcapillary col
umn, packed in-house with Magic C18 AQ 5-m resin (Michrom
Bioresources), and resolved by a nonlinear gradient of 5 to 28%
acetonitrile containing 0.1% formic acid at a flow rate of 300 nl/min
over the course of 80 min. Each survey scan in the Orbitrap was
followed by MS/MS scans of the top nine most intense precursor ions
in the linear ion trap. Tandem spectra acquired were searched against
a human Uniprot database (downloaded January 2015) with target decoy
using the Comet algorithm (version 2014.02) (35). Peptide search param
eters included precursor mass tolerance of 20 parts per million, one
tryptic end for peptide, and differential mass modification to methionine
(+15.999) due to oxidation and serine and threonine (+96.0329)
due to thiophosphorylation. Search results were filtered using Trans
Proteomic Pipeline (36) with a minimal iProphet (37) score of
0.75 and corresponding peptide false discovery rate (FDR) between
0.5 to 1%.
Functional enrichment analysis of CDK2 substrates
A network made up of the candidate substrates were created by
manually inputting the list into the STRING protein query within
Chi et al., Sci. Adv. 2020; 6 : eaaz9899
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Cytoscape (38, 39) and analyzed using the STRING functional en
richment tool with an enrichment FDR value cutoff of 0.05. Select
enriched functional categories were generated on the basis of the
Gene Ontology process category.
SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/16/eaaz9899/DC1
View/request a protocol for this paper from Bio-protocol.
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